Clinical Trials Logo

Lymphoproliferative Disorders clinical trials

View clinical trials related to Lymphoproliferative Disorders.

Filter by:

NCT ID: NCT01352520 Active, not recruiting - Lymphoma Clinical Trials

SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)

Start date: June 2011
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if SGN-35 (brentuximab vedotin) can help to control ALCL, LyP or MF in patients with at least 1 of the 3 skin lymphomas. The safety of the study drug will also be studied.

NCT ID: NCT01273090 Completed - Lymphoma Clinical Trials

Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma

Start date: May 2011
Phase: Phase 1
Study type: Interventional

RATIONALE: Imetelstat sodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I clinical trial is studying the side effects and best dose of imetelstat sodium in treating young patients with refractory or recurrent solid tumors or lymphoma.

NCT ID: NCT01261247 Completed - Clinical trials for Recurrent Mantle Cell Lymphoma

Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Start date: January 17, 2011
Phase: Phase 2
Study type: Interventional

Panobinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. This phase II trial is studying how well panobinostat works in treating patients with relapsed or refractory non-Hodgkin lymphoma

NCT ID: NCT01254578 Completed - Clinical trials for Recurrent Mantle Cell Lymphoma

Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers

Start date: November 24, 2010
Phase: Phase 1
Study type: Interventional

This phase I clinical trial is studying the side effects and the best dose of lenalidomide after donor bone marrow transplant in treating patients with high-risk hematologic cancer. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing.

NCT ID: NCT01231919 Completed - Clinical trials for Chronic Myelomonocytic Leukemia

MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia

Start date: January 2011
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects, best way to give, and best dose of Akt inhibitor MK2206 (MK2206) in treating patients with recurrent or refractory solid tumors or leukemia. MK2206 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT01224769 Completed - Clinical trials for Relapsed or Refractory Chronic Lymphoproliferative Disorders

Bendamustine and Rituximab As Salvage Therapy In Patients With Chronic Lymphoproliferative Disorders

Start date: September 2005
Phase: N/A
Study type: Observational

This retrospective study collects and evaluates the clinical experience reached in Italy on the use of bendamustine alone or combined with rituximab as treatment of patients with relapsed or refractory chronic lymphoproliferative disorders.

NCT ID: NCT01199562 Completed - Clinical trials for Chronic Myelomonocytic Leukemia

Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant

Start date: December 2010
Phase:
Study type: Observational

RATIONALE: Infection prophylaxis and management may help prevent cytomegalovirus (CMV) infection caused by a stem cell transplant. PURPOSE:This clinical trial studies infection prophylaxis and management in treating cytomegalovirus infection in patients with hematologic malignancies previously treated with donor stem cell transplant.

NCT ID: NCT01186224 Recruiting - Multiple Myeloma Clinical Trials

Plerixafor Harvesting And No Chemotherapy for Transplantation of Autologous STem Cells In Cancer (PHANTASTIC)

PHANTASTIC
Start date: May 2010
Phase: N/A
Study type: Interventional

To assess the efficacy and toxicity of plerixafor (AMD 3100) together with granulocyte-colony stimulating factor (G-CSF) for stem cell mobilisation, in patients with myeloma or lymphoma requiring high dose chemotherapy with stem cell rescue.

NCT ID: NCT01177371 Completed - Clinical trials for Recurrent Mantle Cell Lymphoma

High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma

Start date: March 1988
Phase: Phase 2
Study type: Interventional

RATIONALE: Giving high doses of chemotherapy drugs, such as busulfan and cyclophosphamide, before a donor bone marrow transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving cyclosporine, methylprednisolone, and methotrexate after transplant may stop this from happening. PURPOSE: This clinical trial studies high-dose busulfan and high-dose cyclophosphamide followed by donor bone marrow transplant in treating patients with leukemia, myelodysplastic syndrome, multiple myeloma, or recurrent Hodgkin or Non-Hodgkin lymphoma.

NCT ID: NCT01158274 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors

Start date: June 2010
Phase: Phase 1
Study type: Interventional

This phase I clinical trial is studying the side effects and best dose of RO4929097 when given together with capecitabine in treating patients with refractory solid tumors. RO4929097 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving RO4929097 together with chemotherapy may kill more tumor cells.